We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Preventing Hypotension in Parturients With an Elevated Body Mass Index (BMI)

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: November 30, 2011
Last Update Posted: November 2, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Duke University
Information provided by (Responsible Party):
Ronald George, IWK Health Centre
Previous research regarding the use of phenylephrine has excluded obese subjects (BMI >35). This subgroup of patients represents a large portion of the obstetric patient population locally and nationally. It is unclear whether previous research should be extrapolated to the obese patient population. This study is being done to compare the incidence of hypotension, intraoperative nausea and vomiting, and neonatal acidosis between obese patients who receive a prophylactic phenylephrine infusion versus those who receive phenylephrine boluses for the treatment of established hypotension. This study will help us determine whether using a phenylephrine infusion or a phenylephrine bolus is the best way to prevent/treat spinal induced hypotension during cesarean deliveries in obese patients.

Condition Intervention Phase
Hypotension Drug: Phenylephrine bolus Drug: phenylephrine infusion Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double Blind Randomized Controlled Trial of Phenylephrine for the Prevention of Spinal Induced Hypotension in Obese Parturients

Resource links provided by NLM:

Further study details as provided by Ronald George, IWK Health Centre:

Primary Outcome Measures:
  • Incidence of Nausea and Vomiting [ Time Frame: intraoperative ]
  • Incidence of Nausea and Vomiting [ Time Frame: 2 hrs postoperative ]
  • Incidence of Nausea and Vomiting [ Time Frame: 24hrs postoperative ]

Secondary Outcome Measures:
  • Incidence of Hypotension [ Time Frame: intraoperative - predelivery ]
  • Incidence of Hypotension [ Time Frame: intraoperative - postdelivery ]
  • Neonatal Acidosis [ Time Frame: intraoperative ]

Enrollment: 170
Study Start Date: November 2010
Study Completion Date: December 2014
Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Phenylephrine bolus Drug: Phenylephrine bolus
10 ml of 100mcg/ml phenylephrine and placebo infusion
Experimental: Phenylephrine infusion Drug: phenylephrine infusion
60ml infusion of 100mcg/ml phenylephrine and placebo bolus


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • English speaking
  • ASA Physical Status I-II
  • Non-laboring women
  • Single gestations ≥ 36 weeks
  • Obese women (Body Mass Index 35 - 55 kg/m2)
  • Non-emergent CD under spinal anesthesia

Exclusion Criteria:

  • Height < 5'0"
  • Antiemetic drug use in the 24 hours prior to CD
  • Allergy to phenylephrine, or any other standardized medication
  • Hypertensive disease of pregnancy (i.e. mild & severe preeclampsia)
  • Chronic hypertension receiving antihypertensive treatment
  • Severe Cardiac disease in pregnancy with marked functional limitations
  • Patients on Monoamine Oxidase Inhibitors or Tricyclic Antidepressants
  • Subject enrollment in another study involving a study medication within 30 days of CD
  • Any other physical or psychiatric condition which may impair their ability to cooperate with study data collection
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01481740

United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
Canada, Nova Scotia
IWK Health Centre
Halifax, Nova Scotia, Canada, B3H 6K8
Sponsors and Collaborators
IWK Health Centre
Duke University
Principal Investigator: Ronald B George, MD FRCPC IWK Health Centre
  More Information

Responsible Party: Ronald George, Primary Investigator, MD, FRCPC, Assistant Professor, IWK Health Centre
ClinicalTrials.gov Identifier: NCT01481740     History of Changes
Other Study ID Numbers: 4999-01460
First Submitted: July 22, 2011
First Posted: November 30, 2011
Results First Submitted: September 14, 2016
Results First Posted: November 2, 2016
Last Update Posted: November 2, 2016
Last Verified: September 2016

Keywords provided by Ronald George, IWK Health Centre:
spinal induced hypotension
nausea and vomiting
cesarean delivery

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases
Cardiotonic Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Vasoconstrictor Agents
Nasal Decongestants
Respiratory System Agents
Adrenergic alpha-1 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Protective Agents